News & Views
Approval for German Medical Device in China
Jul 17 2017 Comments 0
Gilupi CellCollector®, the first medical device for in vivo CTC isolation, manufactured by Gilupi, was approved by the Chinese registrations agency (China Food and Drug Administration – CFDA) in June. As a result, the Potsdam-based company gains access to one of the most significant geographical markets worldwide. This milestone was reached in close cooperation with Gilupi’s strategic partner, Hebei Viroad Biotechnology Co Ltd (Viroad). Besides its role as strategic partner, Viroad is also the largest investor and shareholder of Gilupi.
Alexander Herrmann, Managing Director of Gilupi GmbH commented: "Viroad is an excellent partner and we achieved this important approval based on their outstanding knowledge of the Chinese market and their regulatory expertise. Together with Viroad, we can realise a rapid market access in China and expect a significant sales growth within the next years.”
The importance of the strategic partnership with Viroad to GILUPI is also pointed out by Brandenburgs Economic State Secretary Hendrik Fischer and the CEO of Brandenburg Invest (WFBB), Sebastian Saule, during their current delegation visit to China. Yesterday, they visit Ms Baozhi Xu the CEO of Hebei Viroad in Shijiazhuang, the capital of Brandenburgs partner province Hebei. State Secretary Fischer explained: “The economic relations with China are very important for the German county Brandenburg. We are pleased that a Brandenburg company is generating attention on the Chinese healthcare market.” WFBB CEO Saule said: “This is a new quality on external economic relations with China and at the same time strengthens the healthcare location Brandenburg. This is of course a wonderful success of the joint efforts in China and Brandenburg, supporting the develop of Gilupi.“
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In this Issue Mass Spectrometry & Spectroscopy - 65th ASMS Conference on Mass Spectrometry and Allied Topics - Reduced injection volume applied to the quantitation of cylindrospermopsin an...
View all digital editions
Sep 25 2017 Berlin, Germany
Sep 26 2017 Sao Paulo, Brazil
Sep 26 2017 Beijing, China
Oct 05 2017 Reading, UK
Oct 10 2017 Beijing, China